2023 / 01

Следующая статья
DOI: 10.24075/medet.2023.001

ОБЗОР

Ингибиторы карбоангидразы в терапии глаукомы

В. В. Страхов1, М. К. Корсаков2, В. Н. Федоров1,2, В. П. Вдовиченко3, А. А. Шетнев2, А. А. Попова2, Н. Н. Вольхин1,2
Информация об авторах

1 Ярославский государственный медицинский университет, Ярославль, Россия

2 Ярославский государственный педагогический университет им. К. Д. Ушинского, Ярославль, Россия

3 Гродненский государственный медицинский университет, Гродно, Республика Беларусь

Для корреспонденции: Михаил Константинович Корсаков
ул. Технопарковая, д. 11/2, г. Ярославль, 150030, Россия; ur.liam@srokkm

Информация о статье

Вклад авторов: В. В. Страхов — разработка концепции и дизайна, редактирование статьи; М. К. Корсаков — ответственность за надлежащее изложение вопросов, связанное с достоверностью данных и целостностью всех частей; В. Н. Федоров — разработка концепции и дизайна, редактирование статьи, ответственность за надлежащее изложение вопросов, связанное с достоверностью данных и целостностью всех частей; В. П. Вдовиченко — сбор, анализ и интерпретация материала, первичное написание; А. А. Шетнев — написание, языковое оформление текста, соответствие научной терминологии; А. А. Попова — оформление списка литературы по порядку упоминания источников в тексте; Н. Н. Вольхин — соблюдение требований оформления статьи для публикации.

Статья получена: 16.01.2023 Статья принята к печати: 21.02.2023 Опубликовано online: 16.02.2023
|
  1. Tham YC, et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014, 121: 2081–2090.
  2. Primary Open-Angle Glaucoma Preferred Practice Pattern 2020 (American Academy of Ophthalmology). Available from URL: https://www.aao.org/preferred-practice-pattern/primary-openangle-glaucoma-ppp
  3. NICE guideline [NG81] Published: 01 November 2017. Available from URL: https://www.nice.org.uk/guidance/ng81/chapter/Recommendations#treatment
  4. Brunton L Laurence. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. Laurence L. Bruce A Chabner, Randa Hilal-Dandan, Bjőrn C Knollmann. 13th Ed, N. Y.: McGraw-Hill. 2018; 451, 1262 p.
  5. Garway-Heath DF, Crabb DP, Bunce C, et al. Latanoprost for open-angle glaucoma (UKGTS): A randomised, multicentre, placebo-controlled trial. Lancet. 2015; 385: 1295-1304.
  6. Whitson JT. Glaucoma: A review of adjunctive therapy and new management strategies. Expert Opin Pharmacother. 2007; 8: 3237–3249.
  7. McKinnon SJ, Goldberg LD, Peeples P, et al. Current management of glaucoma and the need for complete therapy. Am J Manag Care. 2008;14: 20–27.
  8. Li T, Lindsley K, Rouse B, et al. Comparative effectiveness of first-line medications for primary open-angle glaucoma: A systematic review and network meta-analysis. Ophthalmology. 2016; 123: 129–140.
  9. Boland MV, Ervin AM, Friedman DS, et al. Comparative effectiveness of treatments for open-angle glaucoma: A systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2013; 158: 271–279.
  10. van der Valk R, Webers CA, Schouten JS, et al. Intraocular pressure-lowering effects of all commonly used glaucoma drugs: A meta-analysis of randomized clinical trials. Ophthalmology. 2005; 112: 1177–1185.
  11. Cheng JW, Cai JP, Wei RL. Meta-analysis of medical intervention for normal tension glaucoma. Ophthalmology. 2009; 116: 1243– 1249.
  12. Maus TL, Larsson LI, McLaren JW, Brubaker RF. Comparison of dorzolamide and acetazolamide as suppressors of aqueous humor flow in humans. Arch Ophthalmol. 1997 Jan; 115 (1): 45–9.
  13. Stewart W, Halper L, Johnson-Pratt L, Polis A, Hartenbaum D. Tolerability and efficacy of dorzolamide versus acetazolamide added to timolol. J Ocul Pharmacol Ther. 2002 Jun; 18(3): 211–20.
  14. Hutzelmann JE, Polis AB, Michael AJ, Adamsons IA. A comparison of the efficacy and tolerability of dorzolamide and acetazolamide as adjunctive therapy to timolol. Oral to Topical CAI Study Group. Acta Ophthalmol Scand. 1998 Dec; 76(6): 717–22.
  15. Epelde Gonzalo F, Llibre Bombardó J, Martínez Pérez J. Acetazolamide induced acute renal failure without evidence of renal obstruction. An Med Interna. 1998 Aug; 15 (8): 451.
  16. Kodjikian L, Durand B, Burillon C, Rouberol F, Grange JD, Renaudier P. Acetazolamide-induced thrombocytopenia. Arch Ophthalmol. 2004 Oct; 122 (10): 1543–4.
  17. Szawarski P, Hall-Thompson B. Acetazolamide-induced myopia at altitude. Wilderness Environ Med. 2009 Fall; 20 (3): 300–1.
  18. Batke M, Cappell MS. Adynamic ileus and acute colonic pseudo-obstructio. Med Clin North Am. 2008 May; 92 (3): 649–70.
  19. Her Y, Kil MS, Park JH, Kim CW, Kim SS. Stevens-Johnson syndrome induced by acetazolamide. J Dermatol. 2011 Mar; 38 (3): 272–5.
  20. Yuanzhi Liu, Junyi Zhao, Xiaoyan Zhong, Qiming Wei, Yilan Huang. Efficacy and Safety of Brinzolamide as Add-On to Prostaglandin Analogues or β-Blocker for Glaucoma and Ocular Hypertension: A Systematic Review and Meta-Analysis. Front Pharmacol. 2019 Jun 25; 10: 679.
  21. Feldman RM, Tanna AP, Gross RL, Chuang AZ, Baker L, Reynolds A, Prager TC, Additivity Study Group. Comparison of the ocular hypotensive efficacy of adjunctive brimonidine 0.15% or brinzolamide 1% in combination with travoprost 0.004%. Ophthalmology. 2007 Jul; 114 (7): 1248–54.
  22. Bournias T, Lai J. Brimonidine tartrate 0.15%, dorzolamide hydrochloride 2%, and brinzolamide 1% compared as adjunctive therapy to prostaglandin analogs// Ophthalmology. 2009 Sep; 116 (9): 1719–24.
  23. Katsuya Miura, Kunio Ito, Chikahiro Okawa, Kota Sugimoto, Koichi Matsunaga, Yukitaka Uji. Comparison of ocular hypotensive effect and safety of brinzolamide and timolol added to latanoprost. J Glaucoma. Apr-May 2008; 17 (3): 233–7.
  24. Liu JH, Medeiros FA, Slight JR, Weinreb RN. Comparing diurnal and nocturnal effects of brinzolamide and timolol on intraocular pressure in patients receiving latanoprost monotherapy. Ophthalmology. 2009 Mar; 116 (3): 449–54.
  25. Cvetkovic R, Perry C. Brinzolamide: a review of its use in the management of primary open-angle glaucoma and ocular hypertension. Drugs Aging. 2003; 20 (12): 919–47.
  26. Rouland JF, Le Pen C, Gouveia Pinto C, Berto P, Berdeaux G. Cost-minimisation study of dorzolamide versus brinzolamide in the treatment of ocular hypertension and primary open-angle glaucoma: in four European countries. Pharmacoeconomics. 2003; 21 (3): 201–13.
  27. Strahlman E, Tipping R, Vogel R. A double-masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol, and betaxolol. International Dorzolamide Study Group. Arch Ophthalmol. 1995 Aug; 113(8): 1009–16.
  28. Petounis A, Mylopoulos N, Kandarakis A, Andreanos D, Dimitrakoulias N. Comparison of the additive intraocular pressure-lowering effect of latanoprost and dorzolamide when added to timolol in patients with open-angle glaucoma or ocular hypertension: a randomized, open-label, multicenter study in Greece. J Glaucoma. 2001 Aug; 10 (4): 316–24.
  29. Polo V, Larrosa JM, Gomez ML, Pablo L, Honrubia FM. Latanoprost versus combined therapy with timolol plus dorzolamide: IOP-lowering effect in open-angle glaucoma. Acta Ophthalmol Scand. 2001 Feb; 79 (1): 6–9.
  30. Gugleta K. Topical carbonic anhydrase inhibitors and visual function in glaucoma and ocular hypertension. Curr Med Res Opin. 2010.
  31. Holló G, Bozkurt B, Irkec M. Brinzolamide/timolol fixed combination: a new ocular suspension for the treatment of open-angle glaucoma and ocular hypertension. Expert Opin Pharmacother. 2009 Aug; 10 (12): 2015–24.
  32. Frampton JE, Perry CM. Topical dorzolamide 2%/timolol 0.5% ophthalmic solution: a review of its use in the treatment of glaucoma and ocular hypertension. Drugs Aging. 2006; 23 (12): 977–95.
  33. Katz G, Dubiner H, Samples J, Vold S, Sall K. Three-month randomized trial of fixed-combination brinzolamide, 1%, and brimonidine, 0.2%. J AMA Ophthalmol. 2013 Jun; 131 (6): 724–30.
  34. Realini T, Nguyen QH, Katz G, Dubiner H. Fixed-combination brinzolamide 1%/brimonidine 0.2% vs monotherapy with brinzolamide or brimonidine in patients with open-angle glaucoma or ocular hypertension: results of a pooled analysis of two phase 3 studies. Eye (Lond). 2013 Jul; 27 (7): 841–7.
  35. Quang H. Nguyen, Matthew G. McMenemy, Tony Realini, Jess T. Whitson, Stephen M. Goode. Phase 3 Randomized 3-Month Trial with an Ongoing 3-Month Safety Extension of Fixed-Combination Brinzolamide 1%/Brimonidine 0.2%. J Ocul Pharmacol Ther. 2013 Apr; 29 (3): 290–297.
  36. Boyle JE, Ghosh K, Gieser DK, Adamsons IA. A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide. Ophthalmology. 1999 Dec; 106 (12 Suppl): 10–6.
  37. Ormrod D, McClellan K. Topical dorzolamide 2%/timolol 0.5%: a review of its use in the treatment of open-angle glaucoma. Drugs Aging. 2000 Dec;17 (6): 477–96.
  38. Manni G, Denis Ph, Chew P, Sharpe ED, Orengo-Nania S, Coote MA, Laganovska G, Volksone L, Zeyen T, Filatori I, James J, Aung T. The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension. J Glaucoma. Apr-May 2009; 18 (4): 293–300.
  39. Hatanaka M, Grigera DE, Barbosa WL, Jordao M, Susanna RJr. An eight-week, multicentric, randomized, interventional, open-label, phase 4, parallel comparison of the efficacy and tolerability of the fixed combination of timolol maleate 0.5%/brimonidine tartrate 0.2% versus fixed combination of timolol maleate 0.5%/ dorzolamide 2% in patients with elevated intraocular pressure. J Glaucoma. 2008 Dec; 17 (8): 674–9.
  40. Remo Susanna Jr, Wang-Pui Sheu, Latin American Glaucoma Society. Comparison of latanoprost with fixed-combination dorzolamide and timolol in adult patients with elevated intraocular pressure: an eight-week, randomized, open-label, parallel-group, multicenter study in Latin America. Clin Ther. 2004 May; 26 (5): 755–68.
  41. Konstas AG, Schmetterer L, Katsanos A, Hutnik CM, Holló G, Quaranta L, Teus M, Uusitalo H, Pfeiffer N, Katz G. Dorzolamide/ Timolol Fixed Combination: Learning from the Past and Looking Toward the Future. Adv Ther. 2021 Jan; 38 (1): 24–51.